HS-10296

DRUG2 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Non Small Cell Lung CancerNonsmall Cell Lung Cancer

Phase 1

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.Nonsmall Cell Lung Cancer

Start: 2017-05-08End: 2023-03-31Updated: 2023-01-23

Phase 3

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non Small Cell Lung Cancer

Start: 2019-02-01End: 2023-06-30Updated: 2023-01-20

Related Papers

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, <i>EGFR</i> ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)

Cancer Communications2024-07-1715 citations

Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS

Cancer Research2023-04-041 citations

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).

Journal of Clinical Oncology2022-06-0115 citations

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Journal of Clinical Oncology2022-05-17250 citations

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.

2021-11-19106 citations

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

Journal of Clinical Oncology2021-05-2031 citations

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Cancer Research2020-08-1524 citations